New study tailors therapy for aggressive myeloma patients
NCT ID NCT07045168
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study is for people newly diagnosed with multiple myeloma that has a specific genetic marker (+1q), which can make the disease harder to treat. Researchers will use a special scoring system to assign each person a treatment plan that matches their risk level. The goal is to see if this personalized approach leads to better cancer control, as measured by minimal residual disease (MRD) negativity. About 200 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
Conditions
Explore the condition pages connected to this study.